Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT
Sponsor: First Affiliated Hospital of Zhejiang University
Summary
This study employs a prospective, randomized, double-blind, placebo-controlled design. It aims to compare the efficacy of etamsylate versus placebo in preventing bleeding complications in patients with thrombocytopenia following hematopoietic stem cell transplantation.
Official title: Comparison of Etamsylate Versus Placebo to Prevent Bleeding in Hematopoietic Stem Cell Transplantation Recipients:a Randomized, Double-blind, Phase 3, Clinical Study
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
404
Start Date
2025-12-16
Completion Date
2027-10-31
Last Updated
2026-03-02
Healthy Volunteers
No
Interventions
etamsylate
etamsylate Injection, administer by intravenous infusion, diluted with 100ml of 0.9% Sodium Chloride Injection, twice daily.
Placebo
0.9% Sodium Chloride Injection, 100 ml, twice daily, intravenous drip
Locations (1)
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China